Keywords: parke-davis, case, may, green, light, whistleblowers, pfizer
Parke-Davis case
Article | 16 February 2004
Pfizer has set aside $427 million to settle investigations into Parke-Davis' alleged off-label promotion of Neurontin (gab-apentin: Marketletter December 15, 2003) in a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
